KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Net Income towards Common Stockholders: 2011-2024

Historic Net Income towards Common Stockholders for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -$4.8 million.

  • Esperion Therapeutics' Net Income towards Common Stockholders fell 2.90% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 160.12%. This contributed to the annual value of -$4.8 million for FY2024, which is 97.74% up from last year.
  • As of FY2024, Esperion Therapeutics' Net Income towards Common Stockholders stood at -$4.8 million, which was up 97.74% from -$214.5 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Net Income towards Common Stockholders ranged from a high of -$4.8 million in FY2024 and a low of -$273.1 million during FY2021.
  • Its 3-year average for Net Income towards Common Stockholders is -$151.9 million, with a median of -$214.5 million in 2023.
  • As far as peak fluctuations go, Esperion Therapeutics' Net Income towards Common Stockholders crashed by 89.55% in 2021, and later skyrocketed by 97.74% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$144.1 million in 2020, then tumbled by 89.55% to -$273.1 million in 2021, then grew by 13.47% to -$236.3 million in 2022, then grew by 9.21% to -$214.5 million in 2023, then skyrocketed by 97.74% to -$4.8 million in 2024.